JPMorgan Chase & Co. Has $14.06 Million Holdings in Iovance Biotherapeutics Inc (IOVA)
JPMorgan Chase & Co. boosted its holdings in Iovance Biotherapeutics Inc (NASDAQ:IOVA) by 63.4% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 1,779,700 shares of the biotechnology company’s stock after buying an additional 690,527 shares during the period. JPMorgan Chase & Co. owned 2.45% of Iovance Biotherapeutics worth $14,059,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of the business. Legal & General Group Plc purchased a new stake in Iovance Biotherapeutics in the 2nd quarter worth $103,000. Swiss National Bank increased its stake in Iovance Biotherapeutics by 17.4% in the 3rd quarter. Swiss National Bank now owns 104,600 shares of the biotechnology company’s stock worth $811,000 after buying an additional 15,500 shares in the last quarter. Parametric Portfolio Associates LLC purchased a new stake in Iovance Biotherapeutics in the 2nd quarter worth $125,000. Dynamic Technology Lab Private Ltd purchased a new stake in Iovance Biotherapeutics in the 3rd quarter worth $133,000. Finally, Bank of New York Mellon Corp increased its stake in Iovance Biotherapeutics by 7.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 261,692 shares of the biotechnology company’s stock worth $2,028,000 after buying an additional 17,338 shares in the last quarter. Institutional investors and hedge funds own 75.93% of the company’s stock.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) opened at $8.95 on Wednesday. Iovance Biotherapeutics Inc has a 1-year low of $4.45 and a 1-year high of $9.54.
A number of equities research analysts have issued reports on IOVA shares. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Iovance Biotherapeutics in a research note on Thursday, August 31st. Chardan Capital reiterated a “buy” rating and issued a $20.00 price target on shares of Iovance Biotherapeutics in a research note on Friday, September 1st. Jefferies Group reiterated a “buy” rating and issued a $11.00 price target on shares of Iovance Biotherapeutics in a research note on Tuesday, September 5th. Oppenheimer set a $13.00 price target on Iovance Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, September 11th. Finally, Zacks Investment Research raised shares of Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $8.25 price objective for the company in a report on Tuesday, October 17th. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $14.53.
WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/jpmorgan-chase-co-has-14-06-million-holdings-in-iovance-biotherapeutics-inc-iova/1774021.html.
Iovance Biotherapeutics Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics Inc (NASDAQ:IOVA).
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.